IN-B00009

Phase 3Small molecule

HHK inno.N Corporation

IN-B00009 is one of 36 small molecule programs targeting Diabetes Mellitus. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Diabetes MellitusActive, not recruiting

Diabetes MellitusPhase 3

Active, not recruiting

Competition

Competitive Landscape

286 competitors in Diabetes Mellitus

#DrugCompanyPhaseTrials

LY2605541

Eli Lilly

Phase 3

1 2

IN-B00009

HHK inno.N Corporation

Phase 3

1 3

Trulicity

Eli Lilly

Preclinical

2 4

Byetta

AstraZeneca

Preclinical

2 5

Galvus

Novartis

Preclinical

1 6

NOVOLIN R

Novo Nordisk

Preclinical

1 7

Edarbi

Takeda

Preclinical

1 8

Paxil CR

GSK

Preclinical

1 9

Simponi

Johnson & Johnson

Preclinical

1 10

Insulin 320

Novo Nordisk

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 3Not yet recruiting

Efficacy and Safety

NCT07308184

Phase 3Not yet recruiting

Diabetes Mellitus

NCT07192263

Clinical

Trials by Indication[1]

Efficacy and Safety1 trial

Bridge Study to Evaluate the Efficacy and Safety of IN-B00009 Injection in Patients With T2DM Inadequately Controlled by Diet and Exercise Alone

Not yet recruiting·HHK inno.N Corporation·Phase 3·NCT07308184·110 enrolled

Diabetes Mellitus1 trial

Study to Evaluate the Efficacy and Safety of IN-B00009 Injection in Adults With Obesity or Overweight Without Diabetes Mellitus

Not yet recruiting·HHK inno.N Corporation·Phase 3·NCT07192263·300 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for IN-B00009. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IN-B00009 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IN-B00009. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — HK inno.N Corporation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: HHK inno.N Corporation

IN-B00009

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Efficacy and Safety1 trial

Diabetes Mellitus1 trial

References

Drug Info

Quick Facts

Related News